4,671 Shares in Omeros Co. (NASDAQ:OMER) Acquired by Quantbot Technologies LP

Quantbot Technologies LP purchased a new stake in Omeros Co. (NASDAQ:OMER) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 4,671 shares of the biopharmaceutical company’s stock, valued at approximately $46,000.

Several other institutional investors also recently made changes to their positions in OMER. Truvestments Capital LLC raised its position in shares of Omeros by 116.5% in the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 1,669 shares during the period. Picton Mahoney Asset Management increased its stake in Omeros by 692.5% during the fourth quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 4,404 shares during the last quarter. US Bancorp DE purchased a new position in shares of Omeros in the 4th quarter worth about $81,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Omeros in the 4th quarter valued at about $121,000. Finally, BNP Paribas Financial Markets grew its holdings in shares of Omeros by 130.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 7,016 shares during the period. 48.79% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms recently commented on OMER. D. Boral Capital restated a “buy” rating and issued a $36.00 price target on shares of Omeros in a report on Tuesday. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research note on Tuesday. Finally, StockNews.com raised shares of Omeros from a “sell” rating to a “hold” rating in a research report on Tuesday. Three equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $22.50.

Omeros Stock Down 3.8 %

NASDAQ OMER opened at $7.91 on Wednesday. Omeros Co. has a fifty-two week low of $2.61 and a fifty-two week high of $13.60. The business has a 50 day moving average price of $8.64 and a two-hundred day moving average price of $7.61. The stock has a market cap of $458.38 million, a PE ratio of -3.42 and a beta of 2.03.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.